AR053232A1 - CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM. - Google Patents
CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM.Info
- Publication number
- AR053232A1 AR053232A1 ARP060101551A ARP060101551A AR053232A1 AR 053232 A1 AR053232 A1 AR 053232A1 AR P060101551 A ARP060101551 A AR P060101551A AR P060101551 A ARP060101551 A AR P060101551A AR 053232 A1 AR053232 A1 AR 053232A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- heteroaryl
- aryl
- diseases related
- therapeutic agents
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 230000001900 immune effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Derivados de piridina que tienen efecto inhibitorio de la síntesis de citoquinas que están involucradas en reacciones inflamatorias, y que por lo tanto son utiles como agentes terapéuticos para el tratamiento de enfermedades relacionadas con la inflamacion, enfermedades relacionadas con el sistema inmune y enfermedades inflamatorias cronicas. Métodos y un agente antiinflamatorio y analgésico, y composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto representado por la formula (1), o sus sales aceptables para uso farmacéutico, donde R1, R2, R3, R4 y R5 se pueden seleccionar independientemente del grupo que consiste en H, halo, ciano, nitro, acilo, hidroxi, amino, alquilo bajo C1-6, alquenilo bajo C2-6, alcoxilo bajo C1-6, alquiltio C1-6, alquilamino C1-10, cicloalquilamino C4-9, heterocicloalquilamino C4-9, arilamino, acilamino, aciloxilo, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilsulfonilamino C1-6, arilsulfinilo, arilsulfonilo, arilsulfonilamino, arilo, heteroarilo, aralquilo C1-10, heteroaralquilo C1-10, ariloxilo y heteroariloxilo, o pueden formar independientemente un anillo mediante union con un grupo de sustitucion vecino; X es O o S; Y es O o N-R6, donde R6 del grupo que consiste en H, alquilo bajo C1-6, acilo, arilo, heteroarilo, aralquilo C1-10 y heteroaralquilo C1-10; o pueden formar independientemente un anillo mediante union con un grupo de sustitucion vecino R5; dicho arilo se elige del grupo que consiste en fenilo, naftilo y fenilo fusionado; dicho heteroarilo es u anillo heterocíclico de 5 miembros o de 6 miembros, o un anillo heterocíclico fusionado que tiene entre 1 y 3 heteroátomos seleccionados de entre O, N y S; dicho arilo y heteroarilo pueden estar sustituidos con 1 a 4 grupos sustituyentes seleccionados del grupo que consiste en halo, hidroxi, alquilo bajo C1-6, alcoxilo bajo C1-6 y amino.Pyridine derivatives that have an inhibitory effect on the synthesis of cytokines that are involved in inflammatory reactions, and that are therefore useful as therapeutic agents for the treatment of diseases related to inflammation, diseases related to the immune system and chronic inflammatory diseases. Methods and an anti-inflammatory and analgesic agent, and pharmaceutical compositions containing them. Claim 1: A compound represented by formula (1), or its salts acceptable for pharmaceutical use, wherein R1, R2, R3, R4 and R5 can be independently selected from the group consisting of H, halo, cyano, nitro, acyl, hydroxy, amino, lower C1-6 alkyl, lower C2-6 alkenyl, lower C1-6 alkoxy, C1-6 alkylthio, C1-10 alkylamino, C4-9 cycloalkylamino, C4-9 heterocycloalkylamino, arylamino, acylamino, acyloxy, C1 alkylsulfinyl -6, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, arylsulfinyl, arylsulfonyl, arylsulfonylamino, aryl, heteroaryl, C1-10 aralkyl, C1-10 heteroaralkyl, aryloxy and heteroaryloxy groups, or can independently form a ring by joining with a substitution group neighbour; X is O or S; Y is O or N-R6, where R6 of the group consisting of H, C1-6 lower alkyl, acyl, aryl, heteroaryl, C1-10 aralkyl and C1-10 heteroaralkyl; or they can independently form a ring by joining with a neighboring substitution group R5; said aryl is selected from the group consisting of phenyl, naphthyl and fused phenyl; said heteroaryl is a 5-membered or 6-membered heterocyclic ring, or a fused heterocyclic ring having between 1 and 3 heteroatoms selected from O, N and S; said aryl and heteroaryl may be substituted with 1 to 4 substituent groups selected from the group consisting of halo, hydroxy, C1-6 lower alkyl, C1-6 lower alkoxy and amino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050032888 | 2005-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053232A1 true AR053232A1 (en) | 2007-04-25 |
Family
ID=37115350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101551A AR053232A1 (en) | 2005-04-20 | 2006-04-19 | CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM. |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100781704B1 (en) |
| AR (1) | AR053232A1 (en) |
| WO (1) | WO2006112666A1 (en) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008520744A (en) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Anti-inflammatory pyrazolopyrimidine |
| AU2007347115A1 (en) | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| DK2240451T3 (en) | 2008-01-04 | 2017-11-20 | Intellikine Llc | ISOQUINOLINON DERIVATIVES SUBSTITUTED WITH A PURIN USED AS PI3K INHIBITORS |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| BRPI0915231A2 (en) | 2008-07-08 | 2018-06-12 | Intellikine Inc | kinase inhibitor compounds and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| US8722692B2 (en) | 2009-07-30 | 2014-05-13 | Jianwei Che | Compounds and compositions as Syk kinase inhibitors |
| TW201105669A (en) * | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CA2802733C (en) * | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| PE20180318A1 (en) | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | PROCEDURE FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
| WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
| JP6130305B2 (en) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | Combinations of kinase inhibitors and their use |
| WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AR091790A1 (en) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | DERIVATIVES OF ISOQUINOLIN-1-ONA AND ITS USES |
| JP6342805B2 (en) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Substituted pyrazolo [3,4-D] pyrimidine and uses thereof |
| PL2809322T3 (en) | 2012-01-26 | 2019-11-29 | Ptc Therapeutics Inc | Compounds for treating spinal muscular atrophy |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| ES2984771T3 (en) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Substituted tricyclic compounds as FGFR inhibitors |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| CA2880790C (en) | 2012-08-13 | 2020-09-08 | Novartis Ag | Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk) |
| KR20150061651A (en) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Modulation of ire1 |
| LT2914296T (en) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| EA035095B1 (en) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Bicyclic heterocycles as fgfr inhibitors |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| HRP20200341T1 (en) | 2013-10-18 | 2020-06-12 | Celgene Quanticel Research, Inc. | BROMODOMENE (BET) INHIBITORS |
| EP3119397B1 (en) | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EA038045B1 (en) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Bicyclic heterocycles as fgfr inhibitors |
| AR104259A1 (en) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | BROMODOMINUM INHIBITORS |
| CN114230571B (en) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | Solid forms of isoquinolinones, methods of making, compositions comprising, and methods of using the same |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA125216C2 (en) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | COMBINED THERAPY |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| RS66310B1 (en) | 2018-05-04 | 2025-01-31 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220138654A (en) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | Compound for preventing or treating diabetes mellitus |
| JP2024513575A (en) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Combination therapy including FGFR inhibitor and Nectin-4 targeting agent |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (en) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | Tricyclic heterocycles as fgfr inhibitors |
| US20250059207A1 (en) * | 2021-12-29 | 2025-02-20 | 858 Therapeutics, Inc. | 6,6-fused heterocyclic compounds as mettl3 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263498B (en) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| JPH08337583A (en) * | 1995-04-13 | 1996-12-24 | Takeda Chem Ind Ltd | Heterocyclic compound and its production |
| JP2001031679A (en) * | 1998-08-26 | 2001-02-06 | Tanabe Seiyaku Co Ltd | Naphthyridine derivative and method for producing the same |
| WO2000032192A1 (en) * | 1998-11-27 | 2000-06-08 | Takeda Chemical Industries, Ltd. | Drugs |
| WO2002022574A1 (en) * | 2000-09-11 | 2002-03-21 | Takeda Chemical Industries, Ltd. | Tricyclic heterocyclic compound, process for producing the same, and use thereof |
| WO2002074771A1 (en) * | 2001-03-19 | 2002-09-26 | Takeda Chemical Industries, Ltd. | Tricyclic heterocyclic compound, process for producing the same, and use |
| WO2005026166A1 (en) * | 2003-09-16 | 2005-03-24 | 'chemical Diversity Research Institute', Ltd. | Physiologically active composition, pharmaceutical composition, substituted 1,2-dihydro[2,7] naphthyridines, method for the production and use thereof |
-
2006
- 2006-04-10 KR KR1020060032449A patent/KR100781704B1/en not_active Expired - Fee Related
- 2006-04-19 AR ARP060101551A patent/AR053232A1/en unknown
- 2006-04-19 WO PCT/KR2006/001461 patent/WO2006112666A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR100781704B1 (en) | 2007-12-03 |
| WO2006112666A1 (en) | 2006-10-26 |
| KR20060110764A (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053232A1 (en) | CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM. | |
| PE20220931A1 (en) | PYRAZOLO[3,4-B]PYRAZINE-TYPE SHP2 PHOSPHATASE INHIBITORS | |
| DOP2022000278A (en) | CYSTEINE PROTEASE INHIBITORS AND THEIR METHODS OF USE | |
| AR055057A1 (en) | HETEROCICLIC INHIBITORS OF MEK, CRYSTAL FORMS OF THE SAME, PROCESSES FOR THEIR PREPARATION AND METHODS OF USE OF THE SAME IN PHARMACEUTICAL COMPOSITIONS AND MEDICINES FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER OR OF AN INFLAMMATORY CONDITION. | |
| AR043038A1 (en) | PIRAZOLOTRIAZINE COMPOUNDS AND USES OF THE SAME | |
| AR039648A1 (en) | USED ARIL CETONA PIRROLO TRIAZINA COMPOUNDS AS KINASE INHIBITORS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR030553A1 (en) | USE OF DERIVATIVES OF TIAZOLILO 2,4-DISPOSED FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF DISEASES MEDIATION THROUGH CYTOKINES, DERIVATIVES OF TIAZOLYLL 2,4-DISPOSED, PHARMACEUTICAL COMPOSITIONS THAT THEY UNDERTAKED | |
| AR063602A1 (en) | DERIVATIVES OF SPIROINDOLINONE, PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM AND THEIR USE IN THE OBTAINING OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ONCOLOGICAL DISORDERS. | |
| AR048427A1 (en) | DERIVATIVES OF SULFONILPIRROLES WITH INHIBITORY ACTIVITY OF HISTONE DEACETILASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THE SAME FOR THE TREATMENT OF RELATED DISEASES. | |
| AR066583A1 (en) | DERIVATIVES OF 3,3-ESPIROINDOLINONA | |
| AR063458A1 (en) | INHIBITING PIRIDINE DERIVATIVES OF 11BETA HSD1 | |
| AR049126A1 (en) | DERIVATIVES OF 5, 6, 7, 8 - TETRAHYDROIMIDAZO [1,5A] PIRIDINE WITH INHIBITORY ACTIVITY OF ALDOSTERONE SYNTHEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF HYPERALDOSINDISM. | |
| DE60322359D1 (en) | Imidazopyridine derivatives as kinase inhibitors | |
| AR029301A1 (en) | COMPOUNDS DERIVED FROM BIARILO, METHODS FOR THEIR PREPARATION COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS AGONISTS IN BETA-ADRENO-ATIPIC RECEIVERS | |
| AR065499A1 (en) | SERINO PROTEASAS INHIBITORS PHARMACEUTICAL COMPOSITIONS | |
| AR059064A1 (en) | TIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES IN THE TREATMENT OF DISEASES MEDIATED BY PROTEIN KINASE B (PKB), SUCH AS CANCER. | |
| AR058769A1 (en) | PEPTIDIL DEFORMILASE INHIBITORS (PDF), USEFUL FOR THE TREATMENT OF TUBERCULOSIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| MX2021013135A (en) | 3-AMINO-4<i>H</i>-BENZO[<i>E</i>][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2. | |
| AR039256A1 (en) | DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS | |
| MX2010000658A (en) | Pyrimidine derivatives 934. | |
| AR069813A1 (en) | DERIVATIVES OF 2- AMINO-PYRIMIDINE, A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARATION OF THE COMPOUND AND USE OF IT TO PREPARE A MEDICINAL PRODUCT | |
| AR049711A1 (en) | HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE | |
| UY29393A1 (en) | NEW DERIVATIVES OF AMIDAS, ACCEPTABLE PHARMACEUTICAL SALTS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS. | |
| AR053109A1 (en) | DERIVATIVES OF PIPERIDINE AND PIPERAZINE, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE CCR2 CHEMIOQUINE RECEPTOR. | |
| RU2017117559A (en) | GASOLINE DERIVATIVES WITH A SIX-RING RING AS A DPP-4 INHIBITOR AND THEIR APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |